-
Clinical Trials & Development2 months agoStaff perspectives shape cross-sector care for dual diagnosis patients
Mental health services in Denmark are testing whether a simple but demanding promise—no patient with co-occurring mental illness and substance use disorder should ever be turned...
-
Clinical Trials & Development2 months agoAbbVie-backed ADARx plans IPO to bankroll array of clinical-stage siRNA therapies
ADARx has reinvigorated its ambitions to go public as the AbbVie-backed biotech looks to fund ongoing clinical trials of a range of next-gen small interfering RNA...
-
Clinical Trials & Development2 months agoFrench expert consensus on cladribine tablets for relapsing MS beyond year 4
French neurologists have published a pragmatic guide for one of the most pressing unanswered questions in modern multiple sclerosis care: what to do with patients who...
-
Clinical Trials & Development2 months agoTargeting tumor microenvironment cells: new directions in brain metastasis therapy
Brain metastases strike up to 30 percent of cancer patients, bringing headaches, seizures, neurological deficits and a median survival of only six to ten months. Yet...
-
Clinical Trials & Development2 months ago
Roivant’s $14M bet on Bayer’s inhaled hypertension med pays off with phase 2 win
Roivant’s $14 million bet on a pulmonary hypertension drug from Bayer appears to have paid off as the inhaled med aced a phase 2 lung disease...
-
Clinical Trials & Development2 months agoNovartis, Ionis drug failure spurs questions about an emerging class of heart medicines
Pelacarsen didn’t protect heart health despite lowering levels of a protein particle, “Lp(a),” in a large clinical trial — a surprise result with important implications for...
-
Clinical Trials & Development2 months ago
Novartis Announces Lp(a)HORIZON Phase III Topline Results for Pelacarsen in Patients with Elevated Lp(a) and Established Cardiovascular Disease (CVD)
Basel, September 4, 2026 – Novartis today announced that the pelacarsen phase III Lp(a)HORIZON trial, a pioneering cardiovascular outcomes study, did not meet its primary endpoint...
-
Clinical Trials & Development2 months agoSTAT+: Novartis’ experimental cardiovascular drug fails a pivotal study
A closely watched cardiovascular drug from Novartis failed in a pivotal study, the company said Friday, a major blow to the firm.
-
Clinical Trials & Development2 months agoMicro-Bladder Model Demonstrates How Phage Therapy Could Help to Reduce Recurrent UTIs
Researchers used a novel human 3D micro-bladder model to demonstrate how phage therapy could help to reduce recurrent urinary tract infections (UTIs) by attacking the reservoirs...
-
Clinical Trials & Development2 months agoCondition-Specific Meeting Reports and Other Information Related to Patients’ Experience
This webpage provides links to certain publicly available external reports and resources relating to patient experience data. The patient community, patient advocates, researchers, drug developers, and...
LncRNA SBF2-AS1 Worsens Heart Injury After Attack via miR-149-5p/PHLPP2 Axis
Stigmatizing language found in over half of primary care patient records
Research report: The Influence of Renal or Hepatic Impairment on the Pharmacokinetics of Iclepertin (BI 425809): Results from Two Phase I Open-Label, Non-randomised, Single Dose, Parallel Design Studies
Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
